| Identification | Back Directory | [Name]
Y16 | [CAS]
429653-73-6 | [Synonyms]
Y16
Y16, >98%
Y16, 429653-73-6
4-[[3-[(3-Methylphenyl)methoxy]phenyl]methylene]-1-phenyl-3,5-pyrazolidinedione
3,5-Pyrazolidinedione, 4-[[3-[(3-methylphenyl)methoxy]phenyl]methylene]-1-phenyl- | [Molecular Formula]
C24H20N2O3 | [MDL Number]
MFCD03083787 | [MOL File]
429653-73-6.mol | [Molecular Weight]
384.43 |
| Chemical Properties | Back Directory | [density ]
1.273±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble5mg/mL, clear (warmed) | [form ]
powder | [pka]
8.84±0.20(Predicted) | [color ]
, faint yellow to dark orange |
| Hazard Information | Back Directory | [Biological Activity]
Y16 is an inhibitor of G protein-coupled Rho GEFs. It blocks the binding of LARG and Rho with a Kd of 80 nM. | [in vitro]
Y16 (10-30 μΜ; 24 hours; NIH 3T3 cells) could inhibit RhoA-GTP formation induced by serum dose dependently and is specific for RhoA.
Y16 (10-30 μΜ; 24 hours ; NIH 3T3 cells) efficiently inhibits serum or SDF-1α-induced phospho-MLC and phospho-FAK formation, which are downstream of RhoA. Cell Viability Assay | Cell Line: | NIH 3T3 cells | | Concentration: | 10 μΜ, 30 μΜ | | Incubation Time: | 24 hours | | Result: | Inhibited RhoA-GTP formation induced by serum dose dependently and was specific for RhoA. | Western Blot Analysis | Cell Line: | NIH 3T3 cells | | Concentration: | 10 μΜ, 30 μΜ | | Incubation Time: | 24 hours | | Result: | Inhibited serum or SDF-1α-induced phospho-MLC and phospho-FAK formation, which were downstream of RhoA. | | [target]
|
|
|
Tags:429653-73-6
Related Product Information
|
|
4506-66-5
1086639-59-9
380315-80-0
2070014-90-1
4382-63-2
1095382-05-0
193022-04-7
1094614-85-3
1059734-66-5
1395084-25-9
1276105-89-5
1429180-08-4
|
|